MFDS — authorised 24 July 1957
- Marketing authorisation holder: MEDPOINTE PHARM HLC
- Status: likely_approved
🇰🇷 Niaspan in South Korea
MFDS authorised Niaspan on 24 July 1957
Marketing authorisation
Niaspan in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in South Korea
Frequently asked questions
Is Niaspan approved in South Korea?
Yes. MFDS authorised it on 24 July 1957.
Who is the marketing authorisation holder for Niaspan in South Korea?
MEDPOINTE PHARM HLC holds the South Korean marketing authorisation.